Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door
→ While an FDA ruling on Eisai and Biogen’s Alzheimer’s drug lecanemab is imminent, new Biogen CEO Chris Viehbacher is splitting the role of R …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
